Humacyte (NASDAQ:HUMA) Stock Price Up 7.4%

Humacyte, Inc. (NASDAQ:HUMA) rose 7.4% during trading on Wednesday . The stock traded as high as $5.51 and last traded at $5.49. Approximately 389,104 shares were traded during mid-day trading, a decline of 78% from the average daily volume of 1,785,340 shares. The stock had previously closed at $5.11.

Wall Street Analyst Weigh In

HUMA has been the subject of several research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 price objective on shares of Humacyte in a report on Tuesday. Piper Sandler reiterated a “neutral” rating and issued a $4.00 price target on shares of Humacyte in a research note on Tuesday, March 26th. Finally, Benchmark reiterated a “buy” rating and issued a $15.00 price target on shares of Humacyte in a research note on Tuesday.

Humacyte Stock Performance

The company has a current ratio of 8.37, a quick ratio of 8.37 and a debt-to-equity ratio of 0.61. The company’s 50 day moving average is $6.02 and its 200-day moving average is $4.24. The company has a market capitalization of $675.18 million, a P/E ratio of -5.67 and a beta of 1.51.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Friday, May 10th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Equities analysts anticipate that Humacyte, Inc. will post -0.95 EPS for the current fiscal year.

Insider Activity at Humacyte

In other news, Director Gordon M. Binder acquired 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The shares were bought at an average cost of $6.78 per share, with a total value of $339,000.00. Following the transaction, the director now owns 160,000 shares of the company’s stock, valued at approximately $1,084,800. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Gordon M. Binder acquired 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The shares were bought at an average cost of $6.78 per share, with a total value of $339,000.00. Following the transaction, the director now owns 160,000 shares of the company’s stock, valued at approximately $1,084,800. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Laura E. Niklason sold 358,630 shares of the stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $7.08, for a total transaction of $2,539,100.40. Following the sale, the chief executive officer now directly owns 4,830,658 shares in the company, valued at $34,201,058.64. The disclosure for this sale can be found here. In the last ninety days, insiders have bought 54,412 shares of company stock valued at $369,107 and have sold 1,628,820 shares valued at $12,464,121. 23.10% of the stock is currently owned by insiders.

Institutional Trading of Humacyte

A number of institutional investors have recently made changes to their positions in HUMA. Vanguard Group Inc. boosted its holdings in shares of Humacyte by 28.7% during the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after acquiring an additional 896,415 shares during the last quarter. Capstone Investment Advisors LLC purchased a new stake in shares of Humacyte during the 1st quarter valued at about $972,000. Private Advisor Group LLC boosted its holdings in shares of Humacyte by 232.7% during the 1st quarter. Private Advisor Group LLC now owns 317,624 shares of the company’s stock valued at $988,000 after acquiring an additional 222,144 shares during the last quarter. GSA Capital Partners LLP boosted its holdings in shares of Humacyte by 139.5% during the 3rd quarter. GSA Capital Partners LLP now owns 355,918 shares of the company’s stock valued at $1,043,000 after acquiring an additional 207,333 shares during the last quarter. Finally, United Asset Strategies Inc. boosted its holdings in shares of Humacyte by 53.9% during the 4th quarter. United Asset Strategies Inc. now owns 221,308 shares of the company’s stock valued at $629,000 after acquiring an additional 77,500 shares during the last quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.